citalopram has been researched along with Asialia in 7 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This was a randomized, double-blind, placebo- and active comparator-controlled study, in which patients (> or = 18 years) meeting DSM-IV criteria for Major Depressive Disorder (MDD) received duloxetine 60 mg once daily (QD; N = 273), escitalopram 10 mg QD (N = 274), or placebo (N = 137) for 8 weeks." | 9.12 | Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. ( Greist, JH; Mallinckrodt, CH; Nierenberg, AA; Prakash, A; Sambunaris, A; Tollefson, GD; Wohlreich, MM, 2007) |
| "In this randomized trial, patients (diagnosis of DSM-IV-defined major depressive disorder; baseline Hamilton Rating Scale for Depression score of >/= 20) received 1 week of single-blind placebo treatment, followed by 8 weeks of double-blind, fixed-dose treatment with either escitalopram or venlafaxine XR (rapidly titrated to 20 mg/day and 225 mg/day, respectively, in accordance with prescribing information)." | 9.11 | A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. ( Bielski, RJ; Chang, CC; Ventura, D, 2004) |
| "This was a randomized, double-blind, placebo- and active comparator-controlled study, in which patients (> or = 18 years) meeting DSM-IV criteria for Major Depressive Disorder (MDD) received duloxetine 60 mg once daily (QD; N = 273), escitalopram 10 mg QD (N = 274), or placebo (N = 137) for 8 weeks." | 5.12 | Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. ( Greist, JH; Mallinckrodt, CH; Nierenberg, AA; Prakash, A; Sambunaris, A; Tollefson, GD; Wohlreich, MM, 2007) |
| "In this randomized trial, patients (diagnosis of DSM-IV-defined major depressive disorder; baseline Hamilton Rating Scale for Depression score of >/= 20) received 1 week of single-blind placebo treatment, followed by 8 weeks of double-blind, fixed-dose treatment with either escitalopram or venlafaxine XR (rapidly titrated to 20 mg/day and 225 mg/day, respectively, in accordance with prescribing information)." | 5.11 | A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. ( Bielski, RJ; Chang, CC; Ventura, D, 2004) |
| "Escitalopram was used as a control for assay sensitivity." | 2.75 | A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. ( Dellva, MA; Dubé, S; Jones, M; Kielbasa, W; Padich, R; Rao, P; Saha, A, 2010) |
| "Escitalopram is a dual serotonin reuptake inhibitor (SSRI) approved for the treatment of depression and anxiety disorders." | 2.72 | In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. ( Asenbaum, S; Attarbaschi, T; Dudczak, R; Geiss-Granadia, T; Holik, A; Kasper, S; Klein, N; Lanzenberger, R; Mossaheb, N; Pötzi, C; Sacher, J; Spindelegger, C; Tauscher, J, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uher, R | 1 |
| Farmer, A | 1 |
| Henigsberg, N | 1 |
| Rietschel, M | 1 |
| Mors, O | 1 |
| Maier, W | 1 |
| Kozel, D | 1 |
| Hauser, J | 1 |
| Souery, D | 1 |
| Placentino, A | 1 |
| Strohmaier, J | 1 |
| Perroud, N | 1 |
| Zobel, A | 1 |
| Rajewska-Rager, A | 1 |
| Dernovsek, MZ | 1 |
| Larsen, ER | 1 |
| Kalember, P | 1 |
| Giovannini, C | 1 |
| Barreto, M | 1 |
| McGuffin, P | 1 |
| Aitchison, KJ | 1 |
| Dubé, S | 1 |
| Dellva, MA | 1 |
| Jones, M | 1 |
| Kielbasa, W | 1 |
| Padich, R | 1 |
| Saha, A | 1 |
| Rao, P | 1 |
| Bielski, RJ | 1 |
| Ventura, D | 1 |
| Chang, CC | 1 |
| Langworth, S | 1 |
| Bodlund, O | 1 |
| Agren, H | 1 |
| Klein, N | 1 |
| Sacher, J | 1 |
| Geiss-Granadia, T | 1 |
| Attarbaschi, T | 1 |
| Mossaheb, N | 1 |
| Lanzenberger, R | 1 |
| Pötzi, C | 1 |
| Holik, A | 1 |
| Spindelegger, C | 1 |
| Asenbaum, S | 1 |
| Dudczak, R | 1 |
| Tauscher, J | 1 |
| Kasper, S | 1 |
| Nierenberg, AA | 1 |
| Greist, JH | 1 |
| Mallinckrodt, CH | 1 |
| Prakash, A | 1 |
| Sambunaris, A | 1 |
| Tollefson, GD | 1 |
| Wohlreich, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens: SPHERE[NCT02625155] | Phase 4 | 14,000 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| Duloxetine Versus Escitalopram and Placebo in the Treatment of Patients With Major Depression[NCT00073411] | Phase 3 | 675 participants | Interventional | 2003-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for citalopram and Asialia
| Article | Year |
|---|---|
Adverse reactions to antidepressants.
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Male; Middle Ag | 2009 |
A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents; Citalopram; Constipati | 2010 |
A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Citalopram; Cyclohexanols; Delayed-Action Preparations; De | 2004 |
Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; | 2006 |
In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.
Topics: Administration, Oral; Adult; Akathisia, Drug-Induced; Area Under Curve; Cerebellum; Cinanserin; Cita | 2006 |
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Topics: Adult; Antidepressive Agents; Arrhythmias, Cardiac; Citalopram; Depressive Disorder; Double-Blind Me | 2007 |
1 other study available for citalopram and Asialia
| Article | Year |
|---|---|
Citalopram for depression.
Topics: Citalopram; Clinical Trials as Topic; Depression; Dose-Response Relationship, Drug; Double-Blind Met | 1998 |